Patents by Inventor Philip Arthur Hipskind

Philip Arthur Hipskind has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MET antibody drug conjugates
    Patent number: 11167039
    Abstract: Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: November 9, 2021
    Assignee: Eli Lilly and Company
    Inventors: Yiqing Feng, Philip Arthur Hipskind, Renhua Li, Ling Liu, Takako Wilson, Aaron David Wrobleski
  • MET ANTIBODY DRUG CONJUGATES
    Publication number: 20200061204
    Abstract: Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.
    Type: Application
    Filed: November 17, 2017
    Publication date: February 27, 2020
    Inventors: Yiqing FENG, Philip Arthur HIPSKIND, Renhua LI, Ling LIU, Takako WILSON, Aaron David WROBLESKI
  • Notch pathway signaling inhibitor compounds
    Patent number: 10450317
    Abstract: The present invention provides the following compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing said compounds useful as a Notch pathway signaling inhibitor for the treatment of named cancers, sensorineural hearing loss caused by auditory hair cell loss, and inducing auditory hair cell generation.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: October 22, 2019
    Assignees: Eli Lilly and Company, Audion Therapeutics
    Inventors: Julia Marie Clay, Albert Edge, Philip Arthur Hipskind, John C. Gill, Bharvin Kumar Patel, Helmuth Hendrikus Gerardus Van Es, Aaron D. Wrobleski, Gaiying Zhao
  • NOTCH PATHWAY SIGNALING INHIBITOR COMPOUNDS
    Publication number: 20180148456
    Abstract: The present invention provides the following compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing said compounds useful as a Notch pathway signaling inhibitor for the treatment of named cancers, sensorineural hearing loss caused by auditory hair cell loss, and inducing auditory hair cell generation.
    Type: Application
    Filed: July 1, 2016
    Publication date: May 31, 2018
    Inventors: Julia Marie Clay, Albert Edge, Philip Arthur Hipskind, John C. Gill, Bharvin Kumar Patel, Helmuth Hendrikus Gerardus Van Es, Aaron D. Wrobleski, Gaiying Zhao
  • Disubstituted phthalazine hedgehog pathway antagonists
    Patent number: 9000023
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: April 7, 2015
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Bharvin Kumar Patel, Takako Wilson (nee Takakuwa)
  • Glucagon receptor antagonists, preparation and therapeutic uses
    Patent number: 8691856
    Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: April 8, 2014
    Assignee: Eli Lilly and Company
    Inventors: Scott Eugene Conner, Philip Arthur Hipskind, Jianke Li, Guoxin Zhu
  • Notch pathway signaling inhibitor compound
    Patent number: 8569286
    Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt or hydrate, and a pharmaceutical composition containing said compound, or a pharmaceutically acceptable salt or hydrate, useful as a Notch pathway signaling inhibitor for the treatment of cancer.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: October 29, 2013
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Gregory Alan Stephenson
  • Tetrasubstituted pyridazine hedgehog pathway antagonists
    Patent number: 8507490
    Abstract: The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C—R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or trifluoromethyl; R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; R5 is trifluoromethyl or methylsulfonyl; R6 is hydrogen or methyl; and R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R7, R8, R9, R10 and R11 are hydrogen useful in the treatment of cancer.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: August 13, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Jeffrey Daniel Cohen, Philip Arthur Hipskind, Karen Lynn Lobb, Daniel Jon Sall, Michelle Lee Thompson, Takako Wilson (nee Takakuwa)
  • Tetrasubstituted pyridazines hedgehog pathway antagonists
    Patent number: 8445493
    Abstract: The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: May 21, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Takako Wilson (nee Takakuwa), Michelle Lee Thompson, Daniel Jon Sall, Philip Arthur Hipskind
  • Disubstituted phthalazine hedgehog pathway antagonists
    Patent number: 8404687
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: March 26, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Philip Arthur Hipskind, Daniel Jon Sall, Takako Wilson (nee Takakuwa)
  • NOTCH PATHWAY SIGNALING INHIBITOR COMPOUND
    Publication number: 20130029972
    Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt or hydrate, and a pharmaceutical composition containing said compound, or a pharmaceutically acceptable salt or hydrate, useful as a Notch pathway signaling inhibitor for the treatment of cancer.
    Type: Application
    Filed: July 18, 2012
    Publication date: January 31, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventors: Philip Arthur HIPSKIND, Gregory Alan STEPHENSON
  • DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20120316174
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Application
    Filed: August 21, 2012
    Publication date: December 13, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Philip Arthur Hipskind, Bharvin Kumar Patel, Takako Wilson (nee Takakuwa)
  • Disubstituted phthalazine hedgehog pathway antagonists
    Patent number: 8273742
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: September 25, 2012
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Bharvin Kumar Patel, Takako Wilson (nee Takakuwa)
  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 8178528
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: May 15, 2012
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Takako Takakuwa, Cynthia Darshini Jesudason, Robert Alan Gadski, William Joseph Hornback, Richard Todd Pickard, Lisa Selsam Beavers
  • Glucagon receptor antagonists, preparation and therapeutic uses
    Patent number: 8076374
    Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: December 13, 2011
    Assignee: Eli Lilly and Company
    Inventors: Mark Donald Chappell, Scott Eugene Conner, Philip Arthur Hipskind, Jason Eric Lamar, Guoxin Zhu
  • TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20110263602
    Abstract: The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C—R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or trifluoromethyl; R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; R5 is trifluoromethyl or methylsulfonyl; R6 is hydrogen or methyl; and R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R7, R8, R9, R10 and R11 are hydrogen useful in the treatment of cancer.
    Type: Application
    Filed: November 5, 2009
    Publication date: October 27, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Jeffrey Daniel Cohen, Philip Arthur Hipskind, Karen Lynn Lobb, Daniel Jon Sall, Michelle Lee Thompson, Takako Wilson (nee Takakuwa)
  • Thiazole pyrazolopyrimidines CRF1 receptor antagonists
    Patent number: 8030304
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Grant
    Filed: September 17, 2007
    Date of Patent: October 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Chafiq Hamdouchi Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Jason Kenneth Myers, Takako Takakuwa, James Lee Toth
  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 8008296
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I).
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: August 30, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 8008301
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: August 30, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Terry Patrick Finn, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20110190304
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Application
    Filed: October 22, 2009
    Publication date: August 4, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jolie Anne Bastian, Philip Arthur Hipskind, Daniel Jon Sall, Takako Wilson (nee Takakuwa)